CB-011

News alerts, weekly reports and conference planners

Company:

Caribou Biosci

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	CB-011 Sensitive: B - Late Trials CB-011 Sensitive : B	CB-011 Sensitive: B - Late Trials CB-011 Sensitive : B
B2M-HLA-E fusion	Multiple Myeloma	B2M-HLA-E fusion	Multiple Myeloma	CB-011 Sensitive: D – Preclinical CB-011 Sensitive : D	CB-011 Sensitive: D – Preclinical CB-011 Sensitive : D

Associations
(2)